

Soni Savai Pullamsetti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7391743/soni-savai-pullamsetti-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

4,213
citations

35
h-index

64
g-index

109
ext. papers

5,332
ext. citations

9.6
avg, IF

5.23
L-index

#	Paper	IF	Citations
87	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
86	Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry.. <i>Frontiers in Immunology</i> , 2022 , 13, 827719	8.4	0
85	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	5
84	Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1316-1319	10.2	3
83	Depletion of and in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the β Catenin Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 639162	5.7	1
82	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	3
81	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. <i>British Journal of Pharmacology</i> , 2021 , 178, 31-53	8.6	5
80	Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. <i>British Journal of Pharmacology</i> , 2021 , 178, 54-71	8.6	26
79	Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
78	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. <i>Cancers</i> , 2021 , 13,	6.6	1
77	Reply to Zheng. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 1113	10.2	
76	Epigenetic Regulation by in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Circulation</i> , 2021 , 144, 1042-1058	16.7	3
75	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021 , 13,	6.6	2
74	Reprogramming of tumor-associated macrophages by targeting β catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , 2020 , 6, eaaz6105	14.3	35
73	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. <i>Nature Communications</i> , 2020 , 11, 1185	17.4	28
72	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFR α . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1445-1457	10.2	17
71	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3560-3575	15.9	46

70	Hypoxia-inducible factor signaling in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5638-5651	15.9	28
69	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. <i>Global Cardiology Science & Practice</i> , 2020 , 2020, e202010	0.7	1
68	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. <i>Global Cardiology Science & Practice</i> , 2020 , 2020, e202010	0.7	1
67	Metabolism in tumour-associated macrophages: a with the tumour microenvironment. <i>European Respiratory Review</i> , 2020 , 29,	9.8	10
66	Epigenetic Inactivation of the Tumor Suppressor Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. <i>Cancers</i> , 2020 , 12,	6.6	3
65	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020 , 80, 4414-4425	10.1	27
64	Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020 , 9,	7.9	4
63	Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. <i>Scientific Reports</i> , 2020 , 10, 12864	4.9	12
62	Metastasis-Associated Protein 2 Represses NF- κ B to Reduce Lung Tumor Growth and Inflammation. <i>Cancer Research</i> , 2020 , 80, 4199-4211	10.1	3
61	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. <i>Nature Communications</i> , 2019 , 10, 2204	17.4	39
60	A RASSF1A-HIF1 α loop drives Warburg effect in cancer and pulmonary hypertension. <i>Nature Communications</i> , 2019 , 10, 2130	17.4	34
59	EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1188-1190	10.2	1
58	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	407
57	Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1720-1723	15.9	31
56	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. <i>EMBO Molecular Medicine</i> , 2018 , 10, 276-293	12	51
55	Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes. <i>Cell Reports</i> , 2018 , 24, 3339-3352	10.6	18
54	Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. <i>Scientific Reports</i> , 2017 , 7, 3896	4.9	10
53	Identification and Functional Characterization of Hypoxia-Induced Endoplasmic Reticulum Stress Regulating lncRNA (HypERlnc) in Pericytes. <i>Circulation Research</i> , 2017 , 121, 368-375	15.7	41

52	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. <i>Circulation</i> , 2017 , 136, 65-79	16.7	145
51	Vascular Stiffness and Mechanotransduction: Back in the Limelight. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 527-530	10.2	5
50	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	50
49	Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017 , 57, 589-602	5.7	8
48	Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 425-437	10.2	81
47	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. <i>Oncotarget</i> , 2017 , 8, 52995-53016	3.3	30
46	Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. <i>European Respiratory Review</i> , 2016 , 25, 135-40	9.8	23
45	miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. <i>Cardiovascular Research</i> , 2016 , 111, 184-93	9.9	42
44	Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016 , 55, 47-57	5.7	45
43	PAFAH1B1 and the lncRNA NONHSAT073641 maintain an angiogenic phenotype in human endothelial cells. <i>Acta Physiologica</i> , 2016 , 218, 13-27	5.6	15
42	Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). <i>Pulmonary Circulation</i> , 2016 , 6, 448-464	2.7	31
41	The emerging role of epigenetics in pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 903-17	13.6	23
40	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 1137-1149	13.6	57
39	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015 , 70, 1022-32	7.3	75
38	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <i>PLoS ONE</i> , 2015 , 10, e0139037	7.3	66
37	5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. <i>BioMed Research International</i> , 2015 , 2015, 438403	3	48
36	Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 437-47	10.2	121
35	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014 , 20, 1289-300	50.5	183

34	Novel and emerging therapies for pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 394-400	10.2	62
33	MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. <i>Circulation Research</i> , 2014 , 114, 67-78	15.7	138
32	Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. <i>Journal of Immunology</i> , 2014 , 193, 597-609	5.3	125
31	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. <i>International Journal of Cardiology</i> , 2013 , 167, 2630-7	3.2	29
30	The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. <i>Journal of Pathology</i> , 2013 , 229, 242-9	9.4	29
29	Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. <i>Circulation</i> , 2013 , 128, 1214-24	16.7	86
28	Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 897-908	10.2	219
27	Effects of anti-inflammatory vagus nerve stimulation on the cerebral microcirculation in endotoxemic rats. <i>Journal of Neuroinflammation</i> , 2012 , 9, 183	10.1	28
26	Matrix metalloproteinases and their inhibitors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2012 , 40, 766-82	13.6	96
25	Role of Src tyrosine kinases in experimental pulmonary hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 1354-65	9.4	90
24	Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 409-19	10.2	171
23	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 61-74	5.9	9
22	Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. <i>PLoS ONE</i> , 2011 , 6, e18136	3.7	30
21	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. <i>Circulation</i> , 2011 , 123, 1194-204	16.7	34
20	Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor- β . <i>Pulmonary Circulation</i> , 2011 , 1, 259-68	2.7	38
19	The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. <i>Science Translational Medicine</i> , 2011 , 3, 87ra53	17.5	50
18	Glycogen synthase kinase 3 β contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. <i>PLoS ONE</i> , 2011 , 6, e18883	3.7	33
17	Role of epidermal growth factor inhibition in experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 158-67	10.2	99

16	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2010 , 11, 146	7.3	17
15	Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 117-31	5.9	105
14	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , 2010 , 10, 26	3.5	29
13	Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. <i>Molecular Biology of the Cell</i> , 2009 , 20, 4751-65	3.5	73
12	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009 , 297, L658-65	5.8	32
11	Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. <i>Neoplasia</i> , 2009 , 11, 48-56	6.4	80
10	Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. <i>Circulation</i> , 2008 , 118, 2081-90	16.7	121
9	Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 188-96	10.2	66
8	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. <i>BMC Pulmonary Medicine</i> , 2008 , 8, 25	3.5	31
7	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. <i>Respiratory Research</i> , 2007 , 8, 4	7.3	31
6	Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. <i>FASEB Journal</i> , 2007 , 21, 2970-9	0.9	111
5	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. <i>Circulation</i> , 2007 , 115, 2331-9	16.7	118
4	A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. <i>Cancer Research</i> , 2007 , 67, 5443-53	10.1	23
3	Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice. <i>Journal of Immunotherapy</i> , 2006 , 29, 175-87	5	12
2	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 720-727	7	20
1	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 720-7	7	6